Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice

Benzer Materyaller

• A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
  Yazar:: Liu, Bai, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas
  Yazar:: Rosario, Maximillian, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity
  Yazar:: Wong, Hing C, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models
  Yazar:: Xu, Wenxin, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model
  Yazar:: Kim, Peter S, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)